Harbin Medisan Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Harbin Medisan Pharmaceutical Co Ltd working capital to net assets ratio. Harbin Medisan Pharmaceutical Co Ltd (002900) has a Working Capital to Net Assets ratio of -1.7% as of September 2025. Working capital of CN¥-32.18 Million (current assets of CN¥1.19 Billion minus current liabilities of CN¥1.22 Billion) is measured against net assets of CN¥1.90 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
Working capital to net assets ratio of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. This chart shows how Harbin Medisan Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at -1.7%, reflecting working capital of CN¥-32.18 Million against net assets of CN¥1.90 Billion CNY. See Harbin Medisan Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Harbin Medisan Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2012–2024)
Harbin Medisan Pharmaceutical Co Ltd working capital to net assets ratio by year from 2012 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Harbin Medisan Pharmaceutical Co Ltd's balance sheet.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 9.9% | CN¥214.23 Million | CN¥2.16 Billion | CN¥1.47 Billion | CN¥1.26 Billion | ▼ -17.6 pp |
| 2023 | 27.5% | CN¥591.40 Million | CN¥2.15 Billion | CN¥1.44 Billion | CN¥845.03 Million | ▼ -22.5 pp |
| 2022 | 50.0% | CN¥1.03 Billion | CN¥2.05 Billion | CN¥1.62 Billion | CN¥597.73 Million | ▲ +7.9 pp |
| 2021 | 42.1% | CN¥890.58 Million | CN¥2.12 Billion | CN¥1.43 Billion | CN¥536.61 Million | ▼ -5.4 pp |
| 2020 | 47.5% | CN¥851.32 Million | CN¥1.79 Billion | CN¥1.44 Billion | CN¥588.84 Million | ▼ -4.5 pp |
| 2019 | 52.0% | CN¥962.30 Million | CN¥1.85 Billion | CN¥1.69 Billion | CN¥723.30 Million | ▼ -8.9 pp |
| 2018 | 60.8% | CN¥1.20 Billion | CN¥1.97 Billion | CN¥1.65 Billion | CN¥447.19 Million | ▲ +1.3 pp |
| 2017 | 59.5% | CN¥1.09 Billion | CN¥1.83 Billion | CN¥1.36 Billion | CN¥266.62 Million | ▲ +51.1 pp |
| 2016 | 8.4% | CN¥67.80 Million | CN¥808.17 Million | CN¥339.75 Million | CN¥271.95 Million | ▲ +0.6 pp |
| 2015 | 7.8% | CN¥56.97 Million | CN¥727.97 Million | CN¥292.83 Million | CN¥235.86 Million | ▲ +2.5 pp |
| 2014 | 5.4% | CN¥32.59 Million | CN¥609.16 Million | CN¥305.08 Million | CN¥272.49 Million | ▲ +37.2 pp |
| 2013 | -31.9% | CN¥-116.43 Million | CN¥365.13 Million | CN¥308.08 Million | CN¥424.51 Million | ▼ -24.6 pp |
| 2012 | -7.3% | CN¥-25.03 Million | CN¥342.72 Million | CN¥297.76 Million | CN¥322.79 Million | — |